Boone Capital Management LLC holds a focused book of 13 stocks worth $326.4M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened TELEFLEX INC and trimmed MEDTRONIC PLC. Their largest long position is MIRUM PHARMACEUTICALS INC at 12% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1882053/holdings"
Use Arkolith to show BOONE CAPITAL MANAGEMENT LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
40% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Mirum Pharmaceuticals Inc COM | $38.9M | 421.2K | 11.9% | —Held | |
| 2 | Ionis Pharmaceuticals Inc COM | $37.6M | 500.5K | 11.5% | ▲+20% Added · +83K sh | |
| 3 | The Cigna Group COM | $36.7M | 137.5K | 11.2% | ▲+43% Added · +41K sh | |
| 4 | Medtronic PLC SHS | $34.5M | 398.1K | 10.6% | ▼−7.2% Reduced · −31K sh | |
| 5 | Teleflex Incorporated COM | $33.3M | 278.8K | 10.2% | ▲New New position | |
| 6 | Biomarin Pharmaceutical Inc COM | $30.9M | 547.9K | 9.5% | ▲+33% Added · +136K sh | |
| 7 | Guardian Pharmacy Svcs Inc CL A | $23.8M | 631.2K | 7.3% | ▲New New position | |
| 8 | AstraZeneca PLC ORD | $21.7M | 110.1K | 6.7% | ▲New New position | |
| 9 | Unitedhealth Group Inc COM | $21.4M | 79.2K | 6.6% | ▲+28% Added · +17K sh | |
| 10 | Bridgebio Pharma Inc COM | $17.0M | 228.8K | 5.2% | ▲+24% Added · +44K sh | |
| 11 | Avanos Med Inc COM | $16.6M | 1.18M | 5.1% | ▲New New position | |
| 12 | Kodiak Sciences Inc COM | $10.7M | 281.3K | 3.3% | ▼−44% Reduced · −222K sh | |
| 13 | Tenax Therapeutics Inc COM NEW | $3.2M | 200.0K | 1.0% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 13 | $326.4M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 15 | $318.6M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 16 | $305.0M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 11 | $233.2M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 12 | $293.8M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 13 | $296.5M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 17 | $385.8M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 19 | $383.4M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 21 | $494.4M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 21 | $428.4M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 13 | $317.0M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 13 | $278.6M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 12 | $213.6M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 17 | $194.9M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.